FBT - ETF AI Analysis
Top Page
First Trust NYSE Arca Biotechnology Index Fund (FBT)
Rating:70Outperform
Price Target:―
Positive Factors
Strong Recent Performance
The fund has shown strong gains so far this year and over the last few months, indicating solid recent momentum.
Healthy Size and Investor Interest
With several billion dollars in assets, the ETF appears well-established and supported by meaningful investor demand.
Multiple Strong-Performing Biotech Holdings
Several top positions, such as Veracyte, Corcept Therapeutics, Alkermes, and Axsome Therapeutics, have delivered strong year-to-date performance, helping drive the fund’s returns.
Negative Factors
High Sector Concentration in Health Care
Almost all of the ETF’s holdings are in the health care sector, which increases risk if biotechnology stocks face a downturn.
Limited Geographic Diversification
The fund is almost entirely invested in U.S. companies, offering little protection if the U.S. market or regulatory environment becomes less favorable for biotech.
Mixed Performance Among Top Holdings
A few key holdings, including Madrigal Pharmaceuticals and Regeneron, have shown weak year-to-date results, which can drag on overall fund performance.
FBT vs. SPDR S&P 500 ETF (SPY)
AUM2.87B
RegionNorth America
Expense Ratio0.55%
Beta0.71
IssuerFirst Trust
Inception DateJun 19, 2006
Dividend YieldN/A
Asset ClassEquity
Index TrackedNYSE Arca Biotechnology Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume26,599
30 Day Avg. Volume73,368
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
319.63Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering30
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FBT Summary
FBT is an exchange-traded fund that follows the NYSE Arca Biotechnology Index, focusing on U.S. biotech companies within the health care sector. It holds firms working on new drugs, genetic treatments, and advanced medical tests. Well-known names in the fund include Biogen and Regeneron, along with smaller, fast-growing biotech players. Someone might invest in FBT to tap into the potential growth of cutting-edge medical innovations while spreading their money across many biotech stocks instead of picking just one. A key risk is that biotech shares can be very volatile, so the fund’s value can rise and fall sharply with news, trials, and the overall market.
How much will it cost me?The expense ratio for the First Trust NYSE Arca Biotechnology Index Fund (FBT) is 0.54%, which means you’ll pay $5.40 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on a niche sector like biotechnology that requires specialized research and expertise.
What would affect this ETF?The First Trust NYSE Arca Biotechnology Index Fund (FBT) could benefit from advancements in biotechnology and increased demand for innovative medical solutions, especially as the U.S. health care sector continues to grow. However, it may face challenges from regulatory changes, high research costs, or broader economic downturns that could impact funding and investor sentiment in the biotech industry.
FBT Top 10 Holdings
FBT is a pure-play U.S. biotech fund, and its story right now is all about fast-moving innovators. Mid-cap names like Halozyme, Corcept Therapeutics, Natera, and NeoGenomics have been rising, giving the ETF much of its recent spark as investors bet on new therapies and diagnostics. Established giants such as Amgen and Regeneron are steadier anchors, adding stability but not much fireworks. BioNTech, meanwhile, looks more mixed as it works through post-pandemic growing pains. Overall, the fund is highly concentrated in cutting-edge health care, with performance driven by clinical and pipeline news.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Halozyme | 4.46% | $127.37M | $12.17B | 39.40% | 73 Outperform | |
| Corcept Therapeutics | 3.89% | $111.14M | $12.19B | 54.78% | 76 Outperform | |
| NeoGenomics | 3.89% | $111.13M | $2.23B | 117.59% | 55 Neutral | |
| Natera | 3.87% | $110.32M | $47.41B | 95.20% | 73 Outperform | |
| Regeneron | 3.73% | $106.47M | $80.46B | 39.55% | 78 Outperform | |
| BeOne Medicines | 3.68% | $105.03M | $38.80B | 6.84% | 61 Neutral | |
| Repligen | 3.63% | $103.68M | $9.32B | 45.48% | 68 Neutral | |
| Argenx Se | 3.56% | $101.55M | $61.89B | 30.14% | 79 Outperform | |
| Genmab | 3.55% | $101.37M | $19.38B | 16.71% | 76 Outperform | |
| BioMarin Pharmaceutical | 3.52% | $100.58M | $12.71B | 21.43% | 75 Outperform |
FBT Technical Analysis
Positive
―
Price Trends
258.34
Positive
240.52
Positive
223.97
Positive
Market Momentum
2.06
Positive
60.13
Neutral
44.15
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FBT, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 268.27, equal to the 50-day MA of 258.34, and equal to the 200-day MA of 223.97, indicating a bullish trend. The MACD of 2.06 indicates Positive momentum. The RSI at 60.13 is Neutral, neither overbought nor oversold. The STOCH value of 44.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FBT.
FBT Peer Comparison
Comparison Results
Performance Comparison
FBT
First Trust NYSE Arca Biotechnology Index Fund
271.23
91.16
50.62%
IYH
iShares U.S. Healthcare ETF
―
―
―
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
IHI
iShares U.S. Medical Devices ETF
―
―
―
IHE
iShares U.S. Pharmaceuticals ETF
―
―
―
IHF
iShares U.S. Healthcare Providers ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents